Successful treatment with infliximab in a patient with Diffuse Subretinal Fibrosis syndrome.
OBJECTIVE
To report a case of Diffuse Subretinal Fibrosis (DSF) syndrome refractory to immunosuppressive therapy who was successfully treated with anti-tumor necrosis factor-alpha (TNF)-alpha monoclonal antibodies infliximab.


METHODS
Interventional case report.


METHODS
A 23-year-old male with bilateral choroiditis presented sudden dimness of vision associated to nasal scotoma in his right eye. Complete ophthalmic examination with appropriated clinical and laboratorial evaluations was carried out during all follow-up. Inform consent statement and Internal Ethics Board approval were also obtained for an open-label therapy schedule.


RESULTS
Extensive temporal subretinal lesion in his right eye and DSF in the left eye were observed. The patient received intravenous infliximab infusion (5 mg/kg) schema. Four weeks after starting treatment his visual acuity improved with decrease in ocular inflammation.


CONCLUSIONS
This report describes a case of DSF syndrome that responded remarkably well to infliximab treatment suggesting that TNF-alpha could play an important pathogenetic role in this syndrome.
Adán
Alfredo
A
Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona, Spain. amadan@clinic.ub.es
Sanmartí
Raimon
R
Burés
Anniken
A
Casaroli-Marano
Ricardo P
RP
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002833:Choroiditis / Q000188:drug therapy; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D012160:Retina / Q000187:drug effects / Q000473:pathology*; D012164:Retinal Diseases / Q000188:drug therapy* / Q000473:pathology; D025242:Spondylarthropathies / Q000150:complications; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab